PHASE I clinical trial of an oral solution of VP-16-213.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis
D000970:Antineoplastic Agents; D005047:Etoposide; D011034:Podophyllotoxin